A First-In-Human Study to Evaluate Safety, Tolerability, Reactogenicity, and Immunogenicity of JNJ-64300535, a DNA Vaccine, Administered by Electroporation-Mediated Intramuscular Injection, in Participants With Chronic Hepatitis B Who Are on Stable Nucleos(t)Ide Therapy and Virologically Suppressed

NCT03463369 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis B, Chronic

Interventions

BIOLOGICAL: JNJ-64300535
BIOLOGICAL: Placebo
DRUG: Nucleos(t)ide Analogs (NA)

Sponsor

Janssen Sciences Ireland UC